Dataset from A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis

A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.

一项针对动脉粥样硬化（atherosclerosis）患者的临床研究，旨在评估为期12周给药周期内，瑞莱司他（rilapladib）对比安慰剂的安全性、疗效及药代动力学（Pharmacokinetics，PK）。